Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Ratio (2016 - 2026)

Ani Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.38 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 19.45% to 0.38 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.38, a 19.45% increase, with the full-year FY2025 number at 0.38, up 19.45% from a year prior.
  • Equity Ratio hit 0.38 in Q4 2025 for Ani Pharmaceuticals, up from 0.36 in the prior quarter.
  • Over the last five years, Equity Ratio for ANIP hit a ceiling of 0.58 in Q2 2024 and a floor of 0.02 in Q3 2024.
  • Historically, Equity Ratio has averaged 0.17 across 5 years, with a median of 0.0 in 2023.
  • The widest YoY moves for Equity Ratio: up 14211884.6% in 2024, down 716315.91% in 2024.
  • Tracing ANIP's Equity Ratio over 5 years: stood at 0.0 in 2021, then soared by 100.03% to 0.0 in 2022, then surged by 68.08% to 0.0 in 2023, then soared by 14211884.6% to 0.31 in 2024, then grew by 19.45% to 0.38 in 2025.
  • Business Quant data shows Equity Ratio for ANIP at 0.38 in Q4 2025, 0.36 in Q3 2025, and 0.0 in Q2 2025.